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Background: The anticancer activity of metformin has been confirmed against several cancer types in vitro
and in vivo. However, the underlyingmechanisms ofmetformin in the treatment of cancer are not fully un-
derstood. This systematic review aims to discuss the possible anticancermechanism of action ofmetformin.
Method: A search through different databases was conducted, including Medline and EMBASE. Results:
A total of 96 articles were identified of which 56 were removed for duplication and 24 were excluded
after reviewing the title and abstract. A total of 12 research articles were included that describe different
antiproliferative mechanisms that may contribute to the antineoplastic effects of metformin. Conclusion:
This analysis discussed the potential anticancer activity of metformin and highlighted the importance of
AMPK as a potential target for anticancer therapy.
Lay abstract: Metformin is a widely used antidiabetic drug. It is the recommended treatment for Type II
diabetes. Recently published reports claimed that the antidiabetic drug can also protect patients against
cancer. This has led to a widespread interest in the antidiabetic medication as a possible treatment for
cancer. While studies have confirmed the anticancer potential of metformin, the way in which metformin
improves cancer outcome remains unknown. Hence, the current study investigates the reported mecha-
nisms that explain how the antidiabetic drug works as an anticancer agent.
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Type II diabetes mellitus is a metabolic disorder that leads to cardiovascular complications. What is more, people
with diabetes have an increased risk of several common cancers [1–4] as well as a higher mortality rate than the
normal population [5]. Metformin is an oral biguanide agent that was the US FDA approved in 1994 and is the
recommended first-line treatment for Type II diabetes mellitus [6,7]. It is believed that metformin improves glycemia
by acting on the liver via AMPK activation [8].
Metformin is known to reduce hepatic gluconeogenesis and increase skeletal muscle glucose uptake by activating
AMPK, which is a cellular energy sensing enzyme that regulates cellular energy status by undergoing phosphorylation
and increasing activity when ATP levels decrease and AMP levels increase. The change in the ATP:AMP ratio is
used as an indicative marker of energy deficiency [9].
There is a continual increase in the prescription and usage of metformin; data from the Quality Outcomes
Framework in England show that across the whole of the last decade, prescribing of metformin has more than
doubled, from 9.4 million items in 2006/2007 to 20.8 million items in 2016/2017 [10]. Prescribing for Type II
diabetes mellitus has changed considerably, with metformin rising to account for 91.0% of first-line therapy among
newly diagnosed patients with T2DM and 79.9% of add-on therapy for patients on sulfonylureas [11].
In addition to its on-label use as an antidiabetic medication, metformin has other off-label uses, such as for
the treatment of polycystic ovary syndrome, hyperinsulinemia, prediabetes, obesity and metabolic syndrome. Data
from the National Disease and Therapeutic Index (NDTI) database showed that the most common diagnoses
with metformin use were diabetes (34·9%), followed by metabolic syndrome (20·9%), polycystic ovary syndrome
(17.2%) and obesity (6.5%) [12].
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Interestingly, the antidiabetic drug is receiving extensive attention as a potential anticancer treatment following
retrospective reports that showed improved survival rate in different cancer types for diabetic patients using
metformin. The drug is gaining international interest for its potential use to treat/prevent different types of cancer,
cardiovascular disease, ageing and neurological disorders [13]. Data from in vitro and preclinical studies confirmed
the anticancer activity of metformin against several types of cancer, which promoted the initiation of more than 55
clinical trials that aimed to investigate the potential anticancer effect of metformin against endometrial, prostate,
pancreas, lung and breast cancer [14].
However, the underlying mechanism of action of how metformin exerts its anticancer activity is still not
completely understood. Thus, the current manuscript is a systematic review of the literature that aims to analyze
and characterize the different reported mechanisms of the anticancer activity of metformin.
Methods
The current review was performed according to the guidelines shown in the PRISMA statement for reporting
systematic reviews and meta-analyses of studies. That evaluate health care interventions: explanation and elaboration
by Liberati et al. [15].
Search strategy
Articles published within the last 15 years to 15 February 2019 were searched through the available databases
including; Medline via PubMed and EMBASE via Elsevier. We used ‘Metformin’, ‘metformin mechanism of
action’ and ‘metformin and cancer’ as the search terms. The search was restricted to English language studies
including journal articles, theses and conference proceedings.
Study selection & quality
M Aljofan and D Riethmacher carried out the study search, study selection, as well as quality assessment and any
disagreement was solved by discussion. The quality of the studies included were assessed according to the quality
of the body of evidence The GRADE approach [16].
Types of study selected
Experimental studies including in vitro and/or in vivo.
Types of outcome
The primary measures of interest include reported mechanism of actions of metformin other than its hypoglycemic
activity. Secondary measure was the anticancer effect of metformin.
Data extraction
The extracted data included the name of the first author; publication year; methodology and findings.
Publication bias & limitations
In this review, we aimed to analyze the reported mechanisms of antitumor action of metformin, thus, we only
included studies with in vitro analyses, which do not necessarily reflect all aspects of the organism as a whole. Some
studies were not included in the review for reasons including subject duplication, article language and no/limited
access to articles. Another limitation is that some of the reported mechanisms have not yet been reconfirmed. This
may be in part due to the fact that this topic, anticancer activity of metformin, is relatively new and that most of
these studies were published within the last decade or so.
Results
The database search produced 96 articles and no other articles were identified using other sources. A total of 56
articles were removed for duplication and 24 articles were excluded after reviewing the title and abstract. Full text of
the 16 remaining articles was obtained and reviewed for the final inclusion. Three review articles and one irrelevant
study were further excluded. Thus, a total of 12 studies were included in the current review. Figure 1 shows the
flow of information that was searched through the different phases of the current systematic review. Table 1 shows
the list of articles included in the review and a brief summary of the findings.
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Database search yielded 96
81 articles were removed for duplication and irrelevancy
16 articles screened for eligibility
A total of 12 relevant and original research articles were included
A total of 4 articles were excluded for
the following reasons:
Reviews
Did not meet criteria
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Figure 1. Flow of the information searched through the current systematic review. The different stages of search
for the current systematic review. The initial search yielded 96 articles based on their titles, but the majority were
excluded after reviewing the abstract. The remainder were screened and only 12 articles were included in the review.
Confirmation of anti-angiogenic activity of metformin
Mounting evidence from in vitro, in vivo and epidemiological and observational studies reported that metformin
may be an effective treatment or adjuvant for cancer therapy. Initially, in an observational study, Evans et al. reported
a link between the use of metformin and a reduced risk of cancers and cancer-related deaths [29]. The study reported
that metformin use may reduce the risk of cancer in patients with Type II diabetes in a dose–response relationship.
Several studies followed.
For instance, in vitro studies that have reported the putative anticancer effect of metformin including Wu
et al., which reported the effect using iterative genomic screening in C. elegans, identified a genetic pathway
linking metformin to the inhibition of cancer growth and lifespan extension [26]. Also, Zordoky and colleagues
investigated the antiproliferative effect of metformin using triple-negative MDA-MB-231 breast cancer cells. The
results indicated that metformin can significantly inhibit MDA-MB-231 cell growth [27].
Results from animal studies such as that of Chen et al. in 2018, which studied the effect of metformin in
genetic mouse models of pancreatic cancer, claimed that metformin can inhibit tumor growth. They treated the
mice with a daily dose of metformin starting at 6 weeks of age. They showed that mice treated with metformin
presented a prolonged overall survival, and decreased tumor volume and tumor weight [28]. What is more, the
study found that intake of metformin delayed pancreatic tumorigenesis in a cancer mouse model, suppressed
chronic pancreatitis-induced tumorigenesis and showed a promising effect in reducing chronic pancreatitis-induced
pancreatic desmoplastic reaction.
Hanawa et al. presented a study using human data that examined the anti-angiogenic effects of metformin
on patients with endometrioid carcinoma, which is considered the most common histologic type of endometrial
carcinoma and of uterine malignancy overall [30,31]. The study included 27 patients who received metformin for
4–6 weeks prior to the day of scheduled surgery. Initially, they received 750 mg/day; this increased weekly up
to 1500 or 2250 mg/day. The results reported that preoperative metformin treatment significantly reduced the
expression of protein phosphatase 2A (PP2A-B), which is considered a hallmark of antiproliferative effects of
metformin administration [25].
LBK-dependent AMPK activation
In 2006, a study by Zakikhani et al. aimed to investigate the molecular antineoplastic mechanism of metformin on
epithelial cells [17]. The authors hypothesized that metformin exhibits direct antiproliferative actions on epithelial
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Table 1. List of studies included in the review.
No Study Title Year Study design Outcome Ref.
1 Zakikhani et al. Metformin is an AMP
kinase-dependent growth inhibitor
for breast cancer cells
2006 Used insulin sensitive breast cancer
cells
Metformin acts as a growth inhibitor
rather than an insulin sensitizer for
epithelial cells
[17]
2 Deng et al. Metformin targets Stat3 to inhibit
cell growth and induce apoptosis in
triple-negative breast cancers
2012 The effect of metformin was tested
in four different human breast
cancer cell lines
Metformin inhibits Stat3 activation
(P-Stat3) at Tyr705 and Ser727 and
downstream signaling
[18]
3 Liu et al. Activation of AMPK by metformin
promotes renal cancer cell
proliferation under glucose
deprivation through its interaction
with PKM2
2019 The action and mechanism of
metformin were confirmed in two
renal cancer cell lines and BALB/C
nude mice
Antiproliferative effects of
metformin in cancer cells are highly
dependent on the glucose
concentration in the extracellular
environment
[19]
4 Ma et al. Low glucose and metformin-induced
apoptosis of human ovarian cancer
cells is connected to ASK1 via
mitochondrial and endoplasmic
reticulum stress-associated pathways
2019 The activity of metformin was
confirmed using three ovarian
cancer cell lines and in mouse
xenograft model
Metformin induces ER stress and cell
apoptosis, and ASK1 plays an
important role in the antitumor
effect of metformin in vivo
[20]
5 Hart et al. SPHK1 is a novel target of
metformin in ovarian cancer
2019 The activity was confirmed using
human serum samples, ovarian
cancer cell lines and nude mice
model
Anticancer activity of metformin
may be via the regulation of SPHK1
and S1P expression
[21]
6 Wang et al. Metformin induces human
oesophageal carcinoma cell
pyroptosis by targeting the
miR-497/PELP1 axis
2019 The mechanism of action was
determined using human
oesophageal carcinoma cells and
immunodeficient mice
Mechanistically, metformin induces
pyroptosis of ESCC by targeting
miR-497/PELP1 axis
[22]
7 Lu et al. Metformin triggers the intrinsic
apoptotic response in human AGS
gastric adenocarcinoma cells by
activating AMPK and suppressing
mTOR/AKT signaling
2019 The study was performed in vitro
using human AGS gastric
adenocarcinoma cell line
Metformin induces apoptosis may
involve ERK, JNK and p38
MAPK-regulated pathways in AGS
cells
[23]
8 Tseng et al. Metformin treatment suppresses
melanoma cell growth and motility
through modulation of microRNA
expression
2019 The mechanism of action was
determined in two different human
melanoma cell lines
Metformin treatment suppressed
the motility and growth of
melanoma cells due to direct
modulation of miR-192-5p-EFEMP1
and miR-584-3p-SCAMP3 axes in
melanoma cells
[24]
9 Hanawa et al. Antitumor effects of metformin via
indirect inhibition of protein
phosphatase 2A in patients with
endometrial cancer
2018 Human data followed by
confirmation of mechanism of
action using two endometrial cancer
cell lines HEC265 and HEC1B
Metformin reduced the expression
of PP2A in patients with EC and that
the reduction of PP2A expression
was related to the antiproliferative
effect of metformin
[25]
10 Wu et al. An Ancient, unified mechanism for
metformin growth inhibition in
Caenorhabditis elegans and cancer
2016 The results were obtained using
Hela Cells and C. elegans
Anticancer activity of metformin is
attributable to its inhibition of
mitochondrial complex I
[26]
11 Zordoky et al. The antiproliferative effect of
metformin in triple-negative
MDA-MB-231 breast cancer cells is
highly dependent on glucose
concentration: implications for
cancer therapy and prevention
2014 The results were obtained using
triple-negative MDA-MB-231 breast
cancer cells
The antiproliferative effect of
metformin thought to be achieved
through an AMPK-dependent
mechanism
[27]
12 Chen et al. Metformin suppresses cancer
initiation and progression in genetic
mouse models of pancreatic cancer
2017 This is an in vivo study using
genetically modified mice model
(oncogenic Kras-mediated PDAC)
mouse models
The anti-angiogenic effects of
metformin is confirmed and that the
mechanism is likely through AMPK
and or STAT3
[28]
EC: Endometrial cancer; ER: Endoplasmic reticulum; ESCC: Esophageal squamous cell carcinoma; PDAC: Pancreatic ductal adenocarcinoma.
cells. They examined the efficacy of metformin on human breast cancer cells (MCF-7), which is known to be
sensitive to insulin and IGF [32].
However, instead of enhancing insulin or IGF-I-stimulated growth, metformin acted as a growth inhibitor, an
action that the authors claimed to be associated with a suppression of p70S6K phosphorylation. Furthermore,
they examined the effect of metformin on cellular proliferation using several cancer cell lines including the LKB1
null HeLa cell lines. Except, for LKB1 null HeLa, dose–response treatment on several cell lines resulted in growth
inhibition, suggesting that the antiproliferative activity of metformin is most likely achieved via LKB1 signaling,
which aligns with growth inhibition seen on the untransformed MCF-10A human breast epithelial cells [32,33].
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Furthermore, the authors investigated whether the metabolic actions of metformin require AMPK activity similar
to that in other tissues such as muscles or hepatocytes. They not only found that metformin stimulates AMPK
phosphorylation, but also that the phosphorylation was achieved in a dose-dependent manner. To confirm these
findings and to determine whether activation of AMPK by metformin is required for the antiproliferative effects
of metformin, the authors used siRNA against AMPK α1 subunit. Interestingly, the AMPKα1 siRNA reduced the
stimulatory effect of metformin on AMPK phosphorylation and that the reduction was correlated with the levels
of reduced AMPKα1.
This study suggests that metformin’s activation of the AMPK pathway is not confined to hepatocytes but can
be observed in epithelial cells as well. In conclusion, the authors claimed that metformin’s antiproliferative activity
was achieved via an LBK-dependent pathway.
Inhibition of STAT3 activation
Deng et al. studied the antiproliferative antisurvival activity of metformin against six triple-negative breast cancer
cell lines, and found that metformin induced growth inhibition on all of these cell lines [18].
The study showed that metformin significantly reduced both tyrosine and serine phosphorylation of Stat3
(P-Stat3 at Tyr705 or Ser727), reduced P-mTOR and induced P-AMPK/AMPK. Also, the study showed that
metformin inhibits Stat3 activation, either directly or indirectly, through a time- and dose-dependent manner.
To further explore the role of Stat3 in metformin action, in one experiment they transfected these cell lines with
constitutively active Stat3, and in another experiment knocked down Stat3 expression using a lentiviral system.
Interestingly, constitutively active Stat3 expression reduced metformin-associated changes in cell growth and
apoptosis as well as cell signaling in all of the tested triple-negative cancer cells. Whereas, specific knockdown of
Stat3 expression enabled metformin to significantly induce more growth inhibition in each of the Stat3-knockdown
cells compared with the control.
In order to investigate the association between the anticancer activity of metformin and mTOR, the authors
compared the growth inhibition and apoptotic effects of metformin alone or combined with the selective Stat3
inhibitor S3I-201 to that of the mTOR inhibitor rapamycin. The study found that both metformin and S3I-
201 alone induced apoptosis, while the combination was even more potent; however, rapamycin treatment alone
induced mild growth inhibition, but failed to significantly enhance the metformin-associated growth inhibition
when combined with metformin, which indicates that metformin’s effect was not due to its effect upon mTOR.
The study concluded that the anticancer activity of metformin is achieved via the direct or indirect activation
of Stat3. Unlike Zakikhani et al., the study claims that the metformin activation of Stat3 and hence, its antitumor
activities are independent of mTOR.
Metformin antitumor activity is glucose dependent: high glucose improves metformin activity
Since cancer cells encounter nutrient limitations, a study by Liu et al. investigated the effect of nutritional
environment on the anticancer activity of metformin using renal cancer cells. The authors examined whether poor
outcome of metformin in renal cancer cells may be influenced by the nutrient condition [19]. In this study, the
authors used a model of glucose deprivation to study the effect of nutrient limitation in renal cancer cells under
metformin treatment.
The study indicated that cellular treatment with metformin under normal condition resulted in a significant
suppression of cell growth, but that changing the cellular environment from normal to glucose-deprived reversed the
metformin-induced growth suppression and that metformin appears to promote cell growth under this condition.
This finding was aligned with that of Zordoky et al., which investigated the antiproliferative effect of metformin
using triple-negative MDA-MB-231 breast cancer cells. The study suggested that treatment with metformin did
not inhibit the growth of MDA-MB-231 cells cultured in hyperglycemic conditions. However, MDA-MB-231
growth was inhibited by metformin when normoglycemic conditions were used for cell culture.
Unlike previous reports, Liu and colleagues suggested that metformin activation of AMPK is not affected by the
environment, and that treatment with metformin did not produce obvious apoptosis in renal cancer cells under
either normal or glucose-deprived conditions. However, several reports have found the exact opposite and that low
glucose environment was reported to increase AMPK activation [2,18,34–36].
To further test the effect of nutritional environment/food starvation on anticancer activity of metformin, the
authors injected 1 × 106 A498 cells into nude mice, which was supposed to mimic an in vivo form of renal cancer,
and restricted their dietary intake to resemble the effect of glucose deprivation. Food starvation alone slowed, but
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did not suppress, tumor growth. However, the study suggested that under glucose starvation, metformin treatment
did not suppress the tumor growth, but in fact increased its volume.
In addition, the authors tested the expression of proliferation marker, Ki-67, and reported that metformin
treatment suppressed the expression of Ki-67 under normal conditions, but induced its expression under glucose
deprivation. Additionally, the in vivo analysis of Ki-67 revealed that metformin treatment promoted cellular
proliferation in food-starved nude mice and that metformin treatment may increase renal cancer cell proliferation
under glucose deprivation. In conclusion, they suggested that the antiproliferative effects of metformin in cancer
cells are highly dependent on the glucose concentration in the extracellular environment.
Metformin antitumor activity is glucose dependent: low glucose improves metformin activity
A study by Ma et al. investigated the anticancer mechanism of action of metformin on different human ovarian
cancer cells [20]. The study claims that metformin treatment in low glucose environment enhances ovarian cancer
cell cytotoxicity by apoptosis induction via mitochondrial pathway, which was confirmed by the increased ratio of
Bax/Bcl-2.
Also, the combination of low glucose and metformin was shown to enhance the expression of cytosolic cytochrome
c and reduce the mitochondrial membrane potential in cancer cells compared with normal glucose with or without
metformin, indicating that cell apoptosis is triggered by combination of low glucose and metformin, via the
mitochondria-associated pathway. These findings suggested that mitochondrial dysregulation plays an important
role in apoptosis that was induced by the combination of low glucose and metformin.
Additionally, metformin and low glucose treatments resulted in a significant increase in the expression of Noxa,
which is a pro-apoptotic protein associated with mitochondrial damage, and a substantial decrease in the expression
of the anti-apoptotic protein, Bcl-2. Intriguingly, the treatment combination of low glucose and metformin
induced the phosphorylation of the ASK1-dependent pathway, which is a key regulatory component of Noxa
expression [21,37,38].
To determine the involvement of ASK1 in the subcellular localization of Noxa protein, cells were pretreated with
NQDI-1, a pharmacological inhibitor of ASK1. The results showed that the total amount of Noxa and the level
translocated to the mitochondria were significantly decreased, and the expression of Bcl-2 was increased, suggesting
that ASK1 plays an essential role in low glucose and metformin-induced subcellular localization of Noxa.
To further confirm the role of ASK1, knockdown of ASK1 expression using siRNA reduced the loss of mito-
chondrion membrane potential and apoptotic ratio in ovarian cancer cells treated with the combination of low
glucose and metformin, which suggests that low glucose and metformin-induced mitochondrial damage are the
consequence of ASK1/Noxa pathway activation.
Furthermore, the study shows that ASK1 activation is associated with accumulation of reactive oxygen species
(ROS) and further activates downstream signaling including JNK. The analysis of the role of ROS in the activation
of ASK1 and JNK in low glucose environment and metformin treatment demonstrated that the inhibition of
ROS decreased the phosphorylation level of ASK1 in cells treated with the combination of low glucose and
metformin. These results suggest that the accumulation of ROS may have been involved in the low glucose and
metformin-induced loss of mitochondrion membrane potential.
Also, the pretreatment of cancer cells with the ROS scavenger NAC reduced several effects seen with the
combination of low glucose and metformin, including a significant decrease in the loss of mitochondrion membrane
potential, a decrease in the mitochondrial localization of Noxa and a significant inhibition of caspase 3 activity in
cancer cells, suggesting that ROS accumulation is associated with Noxa-mediated mitochondrial damage.
Of note, the study suggested that the combination of low glucose and metformin activate endoplasmic reticulum
stress through ROS that triggers endoplasmic reticulum (ER) stress-associated apoptosis through ROS/ASK1/JNK
pathway. Thus, the study confirmed the antitumor effect of metformin in ovarian cancer cells in vivo, and showed
that metformin decreased tumor volume and weight in a dose-dependent manner as well as effectively induced
ASK1 phosphorylation.
Finally, they claimed that the treatment with metformin alone effectively increased the expression of Grp78,
GADD153 and cleaved caspase 3, suggesting that metformin treatment in the xenograft model could induce ER
stress and cell apoptosis. In conclusion, the study suggested that metformin induces ER stress and cell apoptosis,
and showed that ASK1 plays an important role in the antitumor effect of metformin in vivo.
Future Sci. OA (2019) 5(8) future science group
Antiproliferative mechanisms of metformin Systematic Review
Metformin causes apoptosis via inhibition of S1P
A recent study by Hart et al. investigated the effect of metformin on sphingosine kinases. These bioactive lipids
are a singular group that is believed to regulate tumor progression [38], including the apoptosis- and cell-inducing
ceramides and sphingosine, as well as S1P, which promotes cell growth, proliferation and migration [21,39,40]. Cancer
cell fate is influenced by the balance of ceramide/sphingosine and S1P – this is referred to as the sphingolipid
rheostat [21,40].
First, the authors wanted to determine whether S1P and SPHK1 promote ovarian cancer, cancer cell migration
and invasion. The results of wound closure assays demonstrated that exogenous S1P promoted migration of ovarian
cancer cells and that this effect was attenuated by pretreatment with metformin. Also, they confirmed that S1P
promoted invasion of the ovarian cancer cell line and that metformin treatment reduced this effect.
Second, direct evaluation in ovarian cancer cell lines (in which endogenous levels of SPHK1 are nearly un-
detectable) of the effect of SPHK1 overexpression on several hallmarks of cancer growth, showed that cells with
ectopic SPHK1 expression had a higher rate of migration and proliferated more rapidly than control transfected
cells, confirming that SPHK1 could indeed promote tumorigenicity.
To determine whether metformin modulates the S1P rheostat in ovarian cancer, analysis of serum metabolites
from patients with stage III/IV ovarian cancer was performed. This demonstrated that ovarian cancer patients who
were using metformin for the treatment of Type II diabetes mellitus had significantly lower serum S1P levels than
patients not using metformin.
These results were further supported in an in vitro experiment that aimed to investigate the effects of metformin
on the sphingolipid rheostat, where an ovarian cancer cell line was treated with metformin or control. The results
confirmed that metformin-treated cells had markedly reduced S1P and sphingosine levels while ceramide levels
were increased. Based on these findings the authors claimed that metformin shifts the rheostat toward reduced S1P
production.
Metformin induces apoptosis via ERK, JNK and p38 AMPK-regulated pathways & mitochondrial ROS
Lu and colleagues used human gastric cancer AGS cells to investigate the antiproliferative effect of metformin
on cancer cells and potentially determine the underlying apoptotic mechanisms [23]. After treating the cells with
different drug concentrations over several time points, the study suggested that metformin suppressed cancer cell
growth via the induction of apoptosis in a concentration and time dependent manner. The study also indicated
that metformin at 20, 30 and 40 mM was able in a concentration-dependent manner to produce double-stranded
DNA fragmentation, which is a unique biochemical hallmark of apoptosis. The results of caspase-3/7 activity
analysis indicated that metformin (20, 30 and 40 mM) significantly enhanced the activity of caspase-3/7 in a
concentration-dependent manner, which demonstrates the ability of metformin to trigger apoptosis of AGS cells
that may be caspase-3/7-dependent.
In order to investigate the molecular pathway involved in the anticancer activity of metformin, and whether
or not AMPK is involved, AGS cells were treated with an AMPK inhibitor, compound C and then p-AMPK
(indicative of AMPK activation) and cell viability were analyzed.
The results demonstrated that compound C suppressed phosphorylation of AMPK and significantly reversed
the effect of metformin on cell viability compared with metformin treatment only. This suggests that, for AGS
cells, modulated AMPK signaling mediates metformin-induced apoptosis. Further analyses of the phosphorylation
of AKT (p-AKT), mTOR (p-mTOR) and p70S6K (p-p70S6K) demonstrated that metformin decreased the
phosphorylation of AKT, mTOR and p70S6K without affecting protein expression, which indicates that metformin
enhances apoptosis potentially by targeting AMPK and AKT/mTOR pathway in AGS cells.
Based on different analyses the authors claimed several potential theories of how metformin induces apoptosis.
For instance, the study claimed that the apoptotic mechanism of metformin may involve ERK, JNK and p38
MAPK-regulated pathways in AGS cells, or through an increase in mitochondrion ROS, or through an intrinsic
signaling that induces mitochondria-mediated caspase-dependent apoptosis.
Metformin targets miR-497-PELP1 to induce pyroptosis
The recently published study by Wang et al. investigated the possible antitumor mechanism of metformin on
human esophageal cells [22]. The study aimed to decipher the role of PELP1 in the progression of esophageal
squamous cell carcinoma (ESCC). They studied the role of PELP1 systematically using the Oncomine database
and in vitro by measuring the mRNA and protein levels of PELP1 in different ESCC cell lines. The data from both
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of these tests confirmed that not only the DNA copy, but also the mRNA and protein levels of PELP1 are increased
in human ESCC.
The study suggested that PELP1 plays an important role in ESCC recurrence and elevated levels of PELP1 in
ESCC lead to poor prognosis. This led the researchers to investigate the role of metformin on PELP1 using two
ESCC cell lines that were treated with different concentrations of metformin over different time periods. The results
indicated that metformin downregulated the levels of PELP1 protein and mRNA in a dose- and time-dependent
manner.
The study claimed that cellular treatment with metformin upregulates miR-497, which is an miRNA that was
shown to be significantly downregulated in cancer tissues [41]. Interestingly, the study suggested that PELP1 is a
target for miR-497 and that upregulation of miR-497 will in turn downregulate PELP1. Furthermore, a daily
intraperitoneal injection of metformin at 250 mg/kg bodyweight for 4 weeks in ESCC animal model resulted in a
significant reduction in the size and weight of the tumor.
What is more, RT-qPCR results indicated that the mRNA levels of PELP1 and miR-497 were down- and
upregulated by metformin, respectively. Further analyses showed that the levels of PELP1 in tumors carried
by metformin-treated mice were significantly reduced and the levels of GSDMD, which is a characteristic of
pyroptosis, were significantly increased. GSDMD interacts with membrane phospholipids to form pores in the
plasma membrane that eventually leads to pyroptosis, which is a nontraditional programed cell death characterized
by pore-formation on the plasma membrane resulting in cell swelling and plasma membrane disruption.
Based on both the in vitro and in vivo findings, the study claimed that metformin exerts its anticancer activity
by the induction of nontraditional programed cell death in ESCC through targeting the miR-497-PELP1 axis.
Metformin modulates miR-192-5p-EFEMP1 & miR-584-3p-SCAMP3
Like Wang et al., the recent study by Tseng and colleagues also supports the notion that metformin is likely
to exert its anticancer activity via miRNA regulation [24]. The study used next-generation sequencing (NGS) to
perform small RNA profiling to identify metformin-regulating miRNAs and explore the effects of miRNAs on
antimelanoma cell growth and motility.
The results showed a significant reduction on the migration ability and motility of human melanoma cell lines
A2058 and A375 after a 3-day treatment with 5 mM of metformin. Also, flow cytometry analysis of melanoma cell
cycle after metformin treatment indicated that the number of cells at the S and G2/M phases increased and the
number of cells at the G0/G1 phase decreased compared with those in the control group. Likewise, a significant
increase in the population of apoptotic cells after 5 mM metformin treatment was noticed. These results indicated
that melanoma cell growth could be suppressed after metformin treatment through impairing cell cycle progression
and inducing cellular apoptosis.
Analyses from the next gene sequencing indicated that metformin may produce different gene expression in
different cell lines. For example, metformin treatment resulted in an increase in 41 types of miRNAs expression and
a reduction of 35 types of miRNAs expression in A2058 cells, but the results were different in A375 cells where the
treatment resulted in a significant upregulation of 27 types of miRNAs and downregulated 28 types of miRNAs.
However, based on the fact that metformin suppressed the growth of melanoma cells, it should have
upregulated tumor-suppressive miRNAs and downregulated oncogenic miRNAs. Thus, out of the many
upregulated/downregulated miRNAs, the study selected miR-192-5p and miR584-3p, which were previously
verified to suppress tumors in human cancers to decipher metformin anticancer activity.
Interestingly, an overexpression of miR-192-5p and miR584-3p on melanoma cell growth was observed that
resulted in a clear suppression of colony formation and invasion abilities as well as proliferation, which were partly
improved after miR-192-5p and miR584-3p inhibitor transfection.
Furthermore, microarray analyses identified several potential target genes for miR-192-5p and miR-584-3p
including the two oncogenes EFEMP1 and SCAMP3, which were significantly decreased after transfection with
miR192-5p and miR-584-3p mimics, respectively.
They used siRNA to investigate the effects ofEFEMP1 and SCAMP3 knockdown on melanoma cell growth. They
found that EFEMP1 and SCAMP3 knockdown had considerably suppressed cell colony formation, proliferation
and substantially induced cell cycle arrest at G2/M and increased the sub-G1 population. Furthermore, cell invasion
and migration were clearly suppressed by EFEMP1 and were not changed by SCAMP3 knockdown. In conclusion,
the results suggested that metformin treatment suppressed the motility and growth of melanoma cells due to direct
modulation of miR-192-5p-EFEMP1 and miR-584-3p-SCAMP3 axes in melanoma cells.
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Figure 2. Potential antiproliferative mechanisms of
metformin. Metformin’s potential activation of the
apoptotic pathway. It is thought that metformin inhibits
tumor growth and progression via activation of
apoptosis. For instance, it was claimed that metformin
enhances apoptosis by targeting AMPK and AKT/mTOR
pathways. It was also reported that metformin activates
Stat3 through an mTOR independent manner as well as
via an AMPK/mTOR dependent way.
Discussion
Metformin (dimethylbiguanide) is the recommended first-line treatment for Type II Diabetes Mellitus [37]. Gen-
erally, it is assumed that metformin improves glycemia through AMPK activation and its effect on the liver [42].
However, growing evidence implies that metformin has other target organs including the gut and intestines [36,42].
In addition to its effect against hyperglycemia, the use of metformin was linked to possible reduction in risk
of cancer and cancer-related mortality and that patients with diabetes using metformin were protected against
different types of cancer, such as glioma, endometrial, breast, colon and gastric cancer [43–47].
While the antitumor mechanisms of metformin are not yet known, several reports have confirmed the antiprolif-
erative ability of metformin against different types of cancer through different mechanisms (Figure 2). For example,
several in vitro studies demonstrated that treatment with metformin was capable of inhibiting cellular metastasis
of EC109 esophageal squamous cell carcinoma cells [48], MG63 and U-2 OS osteosarcoma cells [49], and SiHa and
HeLa cervical cancer cells [50].
Furthermore, in a dose- and time-dependent manner, metformin was shown to induce apoptosis in various
cancer cell lines including SKOV3, A2780 and ES2 ovarian cancer cells [51], CAL 27, CAL 33 and UMSCC47
head and neck carcinoma cells [52], HepG2 hepatoma cells [53], B16F10 melanoma cells [54] and paclitaxel-resistant
A2780-PR and cisplatin-resistant ACRP cells [51]. However, in this report we attempted to list and discuss the
mechanisms that were reported as possible ways that metformin may induce its antitumor effects.
Metformin-stimulated activation of AMPK in cells other than hepatocytes will result in control of cellular
proliferation [33], which is also supported by Zakikhan et al., who showed activation of the AMPK pathway by
metformin is not confined to hepatocytes but can be observed in epithelial cells as well [17].
Furthermore, the result of AMPK activation in epithelial cells, such as in breast cancer tissue, may lead to
reduced proliferation, general reduction of mRNA translation and protein synthesis. These findings are supported
by several reports including a study by Stapleton et al. who suggested that in tissues other than liver and muscles,
the α1 isoform, which was shown to be associated with cellular proliferation, is physiologically more important
than the metabolism and energy demand associated α2 isoform [55]. Furthermore, a study investigating the effect
of metformin on breast cancer indicated that metformin reduced cell growth by targeting the AMPK signaling
pathway [23,56].
On the contrary, it was reported that pretreatment with an AMPK antagonist inhibited prostate cancer cell
proliferation [57,58]. Similarly, it was reported that the outcome of AMPK activation depends on the cellular
environment such as that the antitumor effect of metformin-induced AMPK activation is highly dependent on the
glucose concentration in the extracellular environment [59]. For instance, AMPK activation in a normal glucose
environment will induce antiproliferative effects [34]. Also, an in vivo study showed metformin to have a reduced
antitumor activity on control diet mice compared with high-energy diet mice associated with hyperinsulinemia
and accelerated tumor growth [60]. Moreover, Liu et al. suggested that low glucose environment can directly
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Figure 3. The effect of glucose environment on metformin’s antiproliferative activity. The effect of glucose levels of
low/normal on the antiproliferative activity of metformin. Some reports have suggested that glucose starvation
increases ROS production that triggers ER stress induced apoptosis through ROS/ASK1/JNK pathway or via Bcl-2
signaling, which is thought to enhance metformin’s antiproliferative activity. To the contrary, others reported that
low glucose may hinder metformin’s antiproliferative activity and that treatment with metformin significantly
reduced the expression level of the proliferation marker Ki-67 in normal glucose, but the opposite was observed with
in glucose environment.
ER: Endoplasmic reticulum; ROS: Reactive oxygen species.
influence the result of AMPK activation and that the activation of AMPK promotes renal cancer cell proliferation
under stressful metabolic conditions (Figure 3). Similar findings suggested that AMPK activation mediated by
lower ATP/AMP ratio, which represent a tumor microenvironment [35], promotes cellular survival under stressful
metabolic conditions [61,62].
However, the observed survival in a low glucose environment may be due to the Warburg effect, where cancer
cells reprogram their metabolism to promote growth, survival and proliferation [63]. AMPK activation is known
to induce antiproliferative effects in many cancer cells, and it is known that glucose deprivation may temporarily
inhibit this activity, but is very unlikely to be of a significant impact for several reasons. First, the Warburg effect
was suggested in some instances to be a temporary effect [63]; second, prolonged glucose deprivation can induce an
inflammatory response and increase the production of ROS, thus eventually damaging cell membrane and nucleic
acids [64]. Arguably, a low glucose-induced raise in ROS will rather increase cellular apoptosis, thus contributing
further to the antitumor activity of metformin, a theory that has been backed and supported by a number of studies
including that of Menendez et al., which showed that the combination of metformin and glucose withdrawal were
quite lethal to cancer cells [65].
In contrast, Ma et al., reported that glucose deprivation enhanced the antitumor effect of metformin, which
aligns with earlier reports that showed the synergistic effect of combining low glucose with metformin-induced
AMPK activation [65,66]. However, Ma and colleagues argued that the increase in antitumor effect of metformin
does not depend on ROS, which they showed by cellular pretreatment with the ROS scavenger N-acetyl-l-cysteine.
However, a number of reports including that by Yang et al. proved that metformin activates ROS and induces
ER-dependent apoptosis [67]. Furthermore, hypoglycemia [68], hypoxia [1], viral infections [69] and ER-Ca2+ [70] lead
to an ER stress that causes a mitochondrial dysfunction and apoptosis [71], indicating that ROS play a major role
in cancer cell apoptosis under glucose depletion environment and that prolonged ER stress activates apoptosis [72].
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All of the studies included in the current report showed that metformin was able to, directly and indirectly,
inhibit different cancer types in vitro and some have confirmed it in vivo. Metformin can directly act on cancer cells
by targeting the AMPK pathway in tumor cells that control metabolism, angiogenesis, inflammation and cancer
stem cells [73], or by inhibiting cancer growth and proliferation via reducing insulinemia and glycemia [74].
The studies reported a number of interesting potential mechanisms and external factors that could explain
metformin’s antitumor effect. Of note, both the cancer cell sensitivity to metformin and the anticancer mechanism
of actions reported were shown to be cell dependent, thus the different and sometimes conflicting mechanisms
described might be due to the physiological differences between different cells. However, all of the reported theories
of anticancer effect of metformin revolve around or are linked to AMPK activation and the external factors are
mostly glucose related. Therefore, we can speculate that the antiglycemic activity of metformin represents an
important means of its anticancer activity and that it is likely to exert its anticancer effect by targeting AMPK in
cancer tissues.
Conclusion
The current study is a systematic review of the literature that investigates metformin’s antiproliferative mechanisms.
While the current findings provide an insight into the anticancer mechanisms of metformin, it also highlights the
importance of AMPK as a potential target for anticancer therapy. In conclusion, the safety profile, the route of
administration and the long history of use make metformin an ideal candidate for repurposing to include other
uses as well. However, the significant efficacy of metformin to inhibit cancer growth proliferation in vitro and in
vivo, as well as the large number of clinical trials that aim to further investigate its efficacy as a potential anticancer
adjuvant or treatment, reflect the potential that this drug can offer and warrants the need to decipher the exact
mechanisms of its anticancer activity.
Future perspective
Metformin is a relatively safe drug that has been used as an antidiabetic medication for several decades, which
makes it a good candidate for repurposing. Currently, the drug has several off-label uses including the treatment of
symptoms of polycystic ovarian syndrome. While we believe that metformin will have new indications/uses, either
off-label or in-label, added to the existing ones, the indications are unlikely to include anticancer as a monotherapy.
Nonetheless, metformin may be more suited as an adjuvant or as a combination to anticancer regimen. Further
studies are needed to identify cellular targets of metformin that could be utilized in anticancer treatments, as well as
the role of its glucose lowering ability as a potential mechanism or contributing factor. Additionally, future research
should focus on investigating metformin’s tissue distribution in normal and cancer cells, which will probably help
in better understanding its anticancer mechanisms and improve its potential anticancer usage.
Summary points
• Metformin is a widely used antidiabetic drug that has been reported to have antiproliferative activity against
several cancers.
• The antiproliferative mechanism of metformin remains unclear.
• This study investigates the reported mechanisms of action that may contribute to metformin’s antiproliferative
activity.
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